• SB-505124 hydrochloride in Mechanobiology

  2026-09-01

  SB-505124 hydrochloride is a reversible ALK4/5/7 pathway tool for separating TGF-β-driven Smad signaling from downstream fibrosis, differentiation, and cell-mechanics phenotypes. This workflow-focused guide shows how to combine pathway validation, formulation control, AFM-based stiffness measurements, and viability checks for more interpretable experiments.

• Etomoxir Workflows for Fatty Acid Oxidation Research

  2026-09-01

  Use Etomoxir to interrogate CPT-1-dependent fatty acid oxidation in cells and standardized whole-blood immune assays. This guide connects concentration-aware experimental design with cytokine profiling, lipid remodeling, translational models, and practical troubleshooting.

• Trypsin-Responsive Nanomedicine for Acute Pancreatitis

  2026-08-31

  The reference study develops a biomimetic mesoporous organosilica nanoparticle that combines pancreatic acinar-cell targeting with trypsin-triggered BAPTA-AM release. In a mouse model, this design addressed calcium overload and downstream inflammatory and necrotic signaling, illustrating how pathological enzyme activity can guide precision drug delivery in acute pancreatitis.

• 3X FLAG Peptide: Assay Design for Nsp1 Studies

  2026-08-31

  The 3X (DYKDDDDK) Peptide supports more than routine FLAG detection: it can help researchers calibrate binding, design mechanistic controls, and manage metal-sensitive assay conditions. This article connects FLAG assay architecture with the Nsp1–NXF1 mRNA-export mechanism reported in SARS-CoV-2 research.

• HMGB1 Proteomics for Early Diabetic Nephropathy

  2026-08-30

  Peng and colleagues used quantitative serum proteomics, Mfuzz clustering, and WGCNA to identify proteins associated with diabetic nephropathy progression, highlighting HMGB1 as a candidate for early monitoring. The study connects discovery-scale protein profiling with cell and animal validation, while also showing why HMGB1 requires prospective clinical evaluation before routine diagnostic use.

• CD163+ Macrophages and Granulosa Cell Apoptosis in PCOS

  2026-08-29

  Ye et al. link increased CD163 expression and macrophage activity with granulosa cell apoptosis in polycystic ovary syndrome (PCOS) using patient samples, a DHEA-induced mouse model, and macrophage–COV434 co-culture experiments. The work positions ovarian immune-cell dysfunction and soluble CD163 release as measurable components of the inflammatory follicular microenvironment, while also clarifying that DHEA functioned as a disease-modeling stimulus rather than a tested treatment.

• (R)-MG132 in Cervical Cancer Assays

  2026-08-28

  (R)-MG132 is a functionally inactive MG-132 enantiomer that helps separate proteasome-dependent biology from nonspecific stress, cytotoxicity, or metabolic effects. Used beside an active inhibitor, it strengthens cell-based assay proteasome control and mechanistic interpretation in cervical cancer research.

• FH1 and the Next Generation of Liver Models

  2026-08-28

  Functional immaturity remains a central barrier in iPS-derived hepatocyte research. This thought-leadership article examines how FH1 (Catalog No. B3700) can strengthen hepatocyte maturation workflows and how better-defined iHep models may support future studies of dynamically controlled gene expression, including light-inducible RNA regulation.

• Amyloid Beta-peptide (25-35) Assay Guide

  2026-08-27

  A practical, scenario-driven guide to using Amyloid Beta-peptide (25-35) (human), SKU A1039, in reproducible neuronal viability, cytotoxicity, oxidative stress, and amyloid aggregation studies. It connects peptide handling and assay controls with current evidence on amyloid-induced neurotoxicity and microglial signaling.

• SmD2 Acetylation Rewires PARP Inhibitor Sensitivity

  2026-08-27

  This Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a determinant of BRCA1/FANC cassette-exon usage, DNA repair, and PARP inhibitor response in hepatocellular carcinoma. Its results connect p300 and HDAC2 activity with SmD2 stability and support combined HDAC and PARP inhibition as a testable strategy in HCC models.

• OM-MSCs, Golgi Stress, and Stroke Recovery

  2026-08-26

  This study identifies Golgi apparatus stress as a modifiable component of cerebral ischemia/reperfusion injury and shows that olfactory mucosa mesenchymal stem cells reduce this response through PEDF-associated PI3K/Akt/mTOR signaling. Its combined cellular and animal models connect organelle protection, calcium and oxidative stress control, and autophagy regulation, providing a mechanistic framework for evaluating OM-MSC-based neuroprotection.

• Amikacin Sulfate: From MIC to Granuloma Targeting

  2026-08-26

  Amikacin Sulfate is more than a conventional aminoglycoside: its activity, intracellular exposure, and tissue-directed delivery can be evaluated as separate experimental variables. This guide translates granuloma-targeting research into practical assay and study-design decisions.

• AG-126 (Tyrphostin AG-126) Assay Guide

  2026-08-25

  Learn how AG-126 (Tyrphostin AG-126), SKU C4338, can strengthen ERK-focused viability, proliferation, and cytotoxicity workflows without confusing pathway inhibition with cell death. This scenario-based guide covers concentration design, solvent controls, interpretation, handling, and evidence-based product selection.

• Lysis Buffer for Faster Mouse Genotyping

  2026-08-25

  Turn small tail, toe, or ear biopsies into a practical DNA input for mouse genotyping with a workflow built around controlled proteinase K digestion. This guide connects reliable colony genotyping with the experimental design lessons of a 2026 colorectal cancer transcriptomics study—while clearly separating validated product use from translational hypotheses.

• Clasto-Lactacystin β-lactone in RIPK3 Assays

  2026-08-24

  Explore how Clasto-Lactacystin β-lactone can turn proteasome inhibition into a causal assay for viral RIPK3 degradation and necroptosis. This mechanistic framework complements conventional viability workflows by clarifying controls, readouts, and interpretation limits.

8524 records 1/569 page Next 12345 下5页 Last page